Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLD-106
- Development stage
- Preclinical
- Lead developer
- Pelemed
- Modality
- Small Molecules
01
Overview
PLD-106 is a small molecule drug candidate currently in the discovery stage of development by the South Korean biotechnology company Pelemed. It is characterized as a wide-spectrum inhibitor intended for the treatment of solid tumors, specifically Renal Cell Carcinoma (RCC) and Hepatocellular Carcinoma (HCC). While the specific molecular targets have not been publicly disclosed beyond the broad-spectrum designation, the drug is being developed using Pelemed's proprietary medicinal chemistry platform, which focuses on the design of novel kinase inhibitors to overcome resistance in cancer treatment.
Beyond the preview
Go deeper on PLD-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLD-106.